Might look at MP too. Sales and earnings beat estimates per earnings call today; it’s a U.S.-based company. Closed ~ $43.85, + 7.37%. See also ATNM.
Cramer’s investment club site needs to be made aware of last week’s JAMA Network Open further review by MedStar of Amarin’s Reduce-It trial of Vascepa and its projected life-time patient benefit. FWIW, Cramer thinks XBI action is a foretell of biotech bottom today. Our portfolios, largely biotech, were + 4% today, a bit better than gain seen in the Nasdaq composite.